Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5592 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CCT369260
CAS:<p>CCT369260 (compound 1), an orally active inhibitor targeting B-cell lymphoma 6 (BCL6), demonstrates anti-tumor efficacy with an IC50 value of 520 nM [1].</p>Fórmula:C24H31ClF2N6O2Cor e Forma:SolidPeso molecular:508.99AQIM-I
CAS:<p>AQIM-I is a survivin inhibitor that reduces survivin expression and colony formation. It promotes reactive oxygen species (ROS) production, apoptosis, cell cycle arrest, DNA damage, and autophagy. Moreover, AQIM-I effectively inhibits nonsmall cell lung cancer cells A549, with an IC 50 value of 9 nM [1].</p>Fórmula:C17H13IN2O2Cor e Forma:SolidPeso molecular:404.20Anticancer agent 44
<p>Anticancer agent 44 induces apoptosis, is selective, cytotoxic to cancer cells, and minimally toxic to human lymphocytes.</p>Fórmula:C22H13Cl2N3O5S2Cor e Forma:SolidPeso molecular:534.39Mcl-1 inhibitor 9
CAS:<p>Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM.</p>Fórmula:C32H39ClN2O5SCor e Forma:SolidPeso molecular:599.18GNE684
CAS:<p>GNE684 inhibits RIP1; Ki app: 21 nM (human), 189 nM (mouse), 691 nM (rat).</p>Fórmula:C23H24N6O3Pureza:98%Cor e Forma:SolidPeso molecular:432.48Thalidomide-NH-amido-C4-NH2
CAS:<p>Thalidomide-NH-amido-C4-NH2 is a synthetic E3 ligase ligand-linker conjugate composed of a Thalidomide-based cereblon ligand and a linker, which is utilized in the synthesis of PROTAC.</p>Fórmula:C19H23N5O5Peso molecular:401.42RET-IN-11
<p>RET-IN-11 selectively inhibits RET (IC50: 6.20 nM), promotes apoptosis, and hinders cell proliferation and migration.</p>Fórmula:C27H30FN9OCor e Forma:SolidPeso molecular:515.59GQN-B37-E
CAS:<p>GQN-B37-E is an effective selective binder and inhibitor of MCL-1. It binds to the BH3-binding domain of MCL-1. GQN-B37-E demonstrates binding affinity for MCL-1 within the sub-micromolar range (Ki= 0.6 μM), yet shows negligible binding to BCL-2 or BCL-XL.</p>Fórmula:C29H23ClN4O4Cor e Forma:SolidPeso molecular:526.97CDK4/6-IN-10
<p>CDK4/6-IN-10: Oral CDK4 (IC50: 22 nM) & CDK6 (IC50: 10 nM) inhibitor with anti-cancer potential for MM research.</p>Cor e Forma:SolidJAK2/FLT3-IN-1 TFA
<p>JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).</p>Fórmula:C27H35F4N7O3Cor e Forma:SolidPeso molecular:581.61Anticancer agent 53
CAS:<p>Anticancer agent 53 exhibits potent in vitro cytotoxicity, triggers apoptosis, halts S/G2/M cycle, and has antitumor effects without toxicity.</p>Fórmula:C31H25FN4O6SCor e Forma:SolidPeso molecular:600.62NLRP3-IN-78
CAS:<p>NLRP3-IN-78 (compound 21) is an NLRP3 inhibitor with a 46.72% inhibition rate of GSDMD-induced pyroptosis at 5 μM. It binds to the NLRP3 protein and prevents GSDMD-NT oligomerization. Additionally, NLRP3-IN-78 inhibits GSDMD cleavage and upstream NF-κB signaling, demonstrating anti-inflammatory activity.</p>Fórmula:C12H5Cl2N3O4S2Cor e Forma:SolidPeso molecular:390.222D-Cl-amidine hydrochloride
<p>D-Cl-amidine hydrochloride is a potent and highly selective inhibitor of PAD1. It exhibits excellent tolerance and does not induce significant toxicity [1].</p>Fórmula:C14H20Cl2N4O2Cor e Forma:SolidPeso molecular:347.24Murizatoclax
CAS:<p>AMG 397 is an oral MCL1 inhibitor .</p>Fórmula:C42H57ClN4O5SPureza:98%Cor e Forma:SolidPeso molecular:765.4406:0 PE
CAS:<p>06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains. It possesses notable antitumor activity and can inhibit tumor progression in the body. Additionally, it exhibits antiproliferative and pro-apoptotic properties, and serves as a precursor for phosphatidylcholine and phosphatidylethanolamine.</p>Fórmula:C17H34NO8PCor e Forma:SolidPeso molecular:411.43YK5
CAS:<p>YK5 is an allosteric inhibitor pocket of Hsp70 and represents a previously unknown chemical tool to investigate cellular mechanisms associated with Hsp70.</p>Fórmula:C18H24N8O3SPureza:98%Cor e Forma:SolidPeso molecular:432.50VEGFR-2-IN-18
<p>VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.</p>Fórmula:C20H13ClN4O2Cor e Forma:SolidPeso molecular:376.8PARP10/15-IN-2
CAS:<p>PARP10/15-IN-2 (Compound 8h) blocks PARP10/15, has IC50s: 0.15μM/0.37μM, cell-permeable, prevents apoptosis.</p>Fórmula:C15H11FN2O3Cor e Forma:SolidPeso molecular:286.26PLK1-IN-13
CAS:<p>PLK1-IN-13 is a selective, orally active PLK1 inhibitor with an IC50 of 0.27 nM. It also inhibits PLK2 (IC50: 12.72 nM) and PLK3 (IC50: 4.12 nM). PLK1-IN-13 induces cell cycle arrest at the G2 phase, promotes apoptosis, and downregulates the transcription of the cancer-associated oncogene c-MYC. This compound inhibits tumor growth and is applicable for research in acute myeloid leukemia (AML).</p>Fórmula:C29H39N9O2SCor e Forma:SolidPeso molecular:577.744Necrosis inhibitor 3
CAS:<p>Necrosis Inhibitor 3 (compound B3) effectively inhibits necrosis, demonstrating an IC50 of 0.29 nM in HT29 cells [1].</p>Fórmula:C25H26N4O4SCor e Forma:SolidPeso molecular:478.56Bcl-2-IN-7
<p>Bcl-2-IN-7 inhibits Bcl-2, encourages apoptosis in cancer cells, and has anti-tumor activity with various IC50 values.</p>Fórmula:C24H22N4O5S2Cor e Forma:SolidPeso molecular:510.59PD-1/PD-L1-IN-23
CAS:<p>PD-1/PD-L1-IN-23: potent, oral PD-1/PD-L1 inhibitor; L7's ester prodrug; exhibits strong antitumor effects.</p>Fórmula:C32H30BrCl2N3O6Cor e Forma:SolidPeso molecular:703.41RIPK1-IN-28
CAS:<p>RIPK1-IN-28 (compound 13) is an orally active inhibitor of RIPK1. It exhibits inhibitory effects on human I2.1 and Hepa1-6 cells, with IC50 values of 0.4 and 1.2 nM, respectively.</p>Fórmula:C27H24N4O4Cor e Forma:SolidPeso molecular:468.5043′-Hydroxyflavanone
CAS:<p>3′-Hydroxyflavanone is a cyclized flavonoid with anti-tumor properties that induces apoptosis in HeLa cells.</p>Fórmula:C15H12O3Cor e Forma:SolidPeso molecular:240.25Topoisomerase I/II inhibitor 3
<p>Topoisomerase I/II inhibitor 3 suppresses cell growth and induces apoptosis in liver cancer by blocking PI3K/Akt/mTOR.</p>Fórmula:C24H24N2O4Cor e Forma:SolidPeso molecular:404.46Keap1-Nrf2-IN-4
<p>Keap1-Nrf2-IN-4 hinders MGC-803 cell growth (IC50=2.55μM), migration, and induces apoptosis with low toxicity.</p>Fórmula:C26H34N2OCor e Forma:SolidPeso molecular:390.56Anti-inflammatory agent 16
<p>Compound 14 is a peptidomimetic that significantly lowers TNFα, NO, CD40, and CD86, showcasing strong anti-inflammatory effects.</p>Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.44N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride
CAS:<p>N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride (TLCK hydrochloride) is an irreversible serine protease inhibitor that functions by alkylating the histidine residue at the active site, thus inhibiting trypsin and trypsin-like proteases. It effectively inhibits caspase-3, caspase-6, and caspase-7 with IC50 values of 12.0, 54.5, and 19.3 μM, respectively. Additionally, N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride induces apoptosis in HL-60 cells and prevents the reduction of mitochondrial transmembrane potential during the apoptosis process.</p>Fórmula:C14H22Cl2N2O3SPeso molecular:369.31AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99NSD2-IN-1
CAS:<p>NSD2-IN-1: potent, selective NSD2-PWWP1 inhibitor, IC50 0.11 μM, induces gene expression changes, apoptosis, cell cycle arrest.</p>Fórmula:C29H31N5Cor e Forma:SolidPeso molecular:449.59VDR agonist 1
CAS:<p>Compound 28 is a nonsteroidal VDR agonist with 690 nM potency, inducing cell cycle arrest and apoptosis in MCF-7 cells.</p>Fórmula:C32H51N3O2Pureza:98%Cor e Forma:SolidPeso molecular:509.77pan-KRAS-IN-5
CAS:<p>Pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor targeting 5′-UTR RNA G-quadruplexes (rG4s). It induces cell cycle arrest and promotes apoptosis in KRAS-driven cancer cells [1].</p>Fórmula:C31H36FIN4O2Cor e Forma:SolidPeso molecular:642.55PD-1/PD-L1-IN-17
<p>PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 inhibitor (IC50: 26.8 nM).</p>Fórmula:C23H20ClN3O4Cor e Forma:SolidPeso molecular:437.88Lonitoclax
CAS:<p>Lonitoclax is an inhibitor of B-cell lymphoma 2 (Bcl-2). It demonstrates antitumor activity in B-cell and myeloid malignancy models comparable to Venetoclax. Lonitoclax holds potential for research in relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas.</p>Fórmula:C43H45ClN4O5Cor e Forma:SolidPeso molecular:733.294Laulimalide
CAS:<p>Microtubule stabilizer; halts cancer cell growth (IC50: 3-30 nM); arrests cells in prometaphase; prevents bipolar spindle formation.</p>Fórmula:C30H42O7Cor e Forma:SolidPeso molecular:514.65EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Fórmula:C28H23N7OCor e Forma:SolidPeso molecular:473.53MTX-216
CAS:<p>MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.</p>Fórmula:C22H14Cl2FN5O2SCor e Forma:SolidPeso molecular:502.348LSD1/ER-IN-1
<p>LSD1/ER-IN-1 inhibits ER & LSD1 (IC50: 1.55 μM), and fights MCF-7 breast cancer (IC50: 8.79 μM).</p>Fórmula:C23H18FNO6SCor e Forma:SolidPeso molecular:455.46Topoisomerase I/II inhibitor 4
<p>Topoisomerase I/II inhibitor 4 halts cell growth and spread, induces apoptosis, and is used in liver cancer research.</p>Fórmula:C27H21N5O6Cor e Forma:SolidPeso molecular:511.49Pim-1 kinase inhibitor 10
CAS:<p>Pim-1 Kinase Inhibitor 10 (compound 13a) acts as both a competitive and non-competitive inhibitor of PIM-1/2 kinase, promoting cell apoptosis and displaying anticancer properties. Additionally, this compound triggers the activation of caspase 3/7 [1].</p>Fórmula:C21H13N3O3Cor e Forma:SolidPeso molecular:355.35TAI-95
CAS:<p>TAI-95 is an inhibitor of highly expressed cancer protein 1 (Hec1).</p>Fórmula:C24H23N5O3S2Cor e Forma:SolidPeso molecular:493.60Thalidomide-O-PEG4-amine TFA
CAS:<p>Thalidomide-O-PEG4-amine TFA is a synthetic E3 ligase ligand-linker conjugate, composed of a cereblon ligand derived from Thalidomide and a single linker.</p>Fórmula:C25H32F3N3O11Peso molecular:607.53MI-888 TFA
CAS:<p>MI-888 (TFA) is an orally active inhibitor of the MDM2-p53 interaction with a Ki of 0.44 nM. It can induce rapid, complete, and durable tumor regression in xenograft mouse models.</p>Fórmula:C30H33Cl2F4N3O5Cor e Forma:SolidPeso molecular:662.5Antiproliferative agent-8
<p>Compound 5a, an anticancer agent, enhances P53 and has antiproliferative effects.</p>Fórmula:C22H16ClN3O3Cor e Forma:SolidPeso molecular:405.83VEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Fórmula:C29H22BrN5SCor e Forma:SolidPeso molecular:552.49Thalidomide-Piperazine-PEG1-NH2
CAS:<p>Thalidomide-Piperazine-PEG1-NH2 is a synthetic E3 ligase ligand-linker conjugate, featuring a cereblon ligand based on Thalidomide and a single linker.</p>Fórmula:C21H27N5O5Peso molecular:429.472-Deoxy-L-ribose
CAS:<p>2-Deoxy-L-ribose is the stereoisomer of 2-Deoxy-D-ribose and can inhibit the anti-apoptotic effects of 2-Deoxy-D-ribose. Additionally, 2-Deoxy-L-ribose is capable of suppressing tumor cell metastasis by downregulating thymidine phosphorylase overexpression.</p>Fórmula:C5H10O4Cor e Forma:SolidPeso molecular:134.13(R)-SL18
CAS:<p>(R)-SL18 is a degrader of ANXA3 that facilitates its breakdown via ubiquitination. This compound can inhibit the proliferation, migration, invasion, and colony formation of breast cancer cells, while also inducing apoptosis. (R)-SL18 is applicable for research in triple-negative breast cancer.</p>Fórmula:C26H21ClN6O5S2Cor e Forma:SolidPeso molecular:597.065PD-L1/VISTA-IN-1
CAS:<p>PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.</p>Fórmula:C22H24N4O4Cor e Forma:SolidPeso molecular:408.45SIRT-IN-7
CAS:<p>SIRT-IN-7 (Compound 7ba) is a SIRT inhibitor. It effectively suppresses the expression of SIRT1, SIRT2, and SIRT3, leading to increased acetylation and activation of p53. Additionally, SIRT-IN-7 inhibits the proliferation of breast cancer cells and induces apoptosis and autophagy, demonstrating antitumor activity.</p>Fórmula:C24H16BrClN2OSCor e Forma:SolidPeso molecular:495.819
